The fresh energy brought by the revitalized research attention offers an opportunity to more closely integrate novel drug discovery, residue monitoring, and ...

Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key ...

The ancient Greek physician and botanist Dioscorides is considered by many to be the father of pharmacology for authoring De ...

In this paper, the potential applications of control technology to clinical pharmacology are discussed, specifically the control of drug dosing. The use of closed-loop control for clinical ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the ...

Natural products are essential sources of bioactive compounds for drug discovery. While earlier drug development relied on targeting single molecules to ...

ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

Gemcitabine, a drug with established efficacy against a number of solid tumors, has therapeutic limitations due to its rapid metabolic inactivation. The aim of this study was the development of an ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

The primary pharmacokinetic interactions with smoking occur with drugs that are CYP1A2 substrates, such as caffeine, clozapine, fluvoxamine, olanzapine, tacrine, and theophylline.